Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas.

Area of Science:

• Oncology
• Hematology
• Clinical Trials

Background:

• Advanced aggressive non-Hodgkin's lymphoma presents a significant treatment challenge.
• Combined modality therapy is a cornerstone in managing aggressive lymphomas.

Purpose of the Study:

• To evaluate the efficacy of a novel 3-phase combined modality program for untreated advanced aggressive non-Hodgkin's lymphoma.
• To assess complete remission and long-term survival rates in patients receiving this intensive treatment regimen.

Main Methods:

• Forty-six patients received induction chemotherapy (cyclophosphamide, hydroxyl-daunomycin, vincristine, prednisone, procarbazine [CHOP(P)]).
• Consolidation involved radiotherapy (involved field or total body irradiation [TBI]) and non-marrow toxic chemotherapy.
• A third phase included four additional cycles of CHOP(P) chemotherapy without maintenance therapy.
• High-dose involved field radiation was limited to <50% of the marrow-bearing skeleton; 82% received TBI (132 rad).

Main Results:

• A complete remission rate of 83% (38/46 patients) was achieved.
• Of 44 evaluable patients, 66% (29/44) remain in complete remission.
• Among 36 patients receiving TBI, 61% (22/36) remain in complete remission up to 26 months.

Conclusions:

• The 3-phase combined modality program, including CHOP(P) chemotherapy and TBI, demonstrates high complete remission and durable survival rates.
• This intensive regimen offers a promising therapeutic option for patients with advanced aggressive non-Hodgkin's lymphoma.
• Further follow-up is warranted to determine the long-term outcomes and potential late toxicities.